Innovent’s Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026 PR NewswireOphthalmology venture grabs investors’ attention, raises $330 million statnews.comOllin nets $330M to run Phase 3 trials of Vabysmo challenger from China Endpoints NewsOllin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026 Business WireOllin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlet Fierce Biotech